Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2E1 | P05181 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23093177 | 0.84 | ERN1 (0.42) | CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL23092877 | 0.82 | CA1 (0.45) | CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL19043692 | 0.80 | MEN1 (0.39) | LMNAMEN1THRBBLMKMT2A | |
| SCHEMBL20621041 | 0.80 | MEN1 (0.39) | LMNAMEN1THRBBLMKMT2A | |
| SCHEMBL20102299 | 0.80 | ERN1 (0.41) | CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL18810582 | 0.80 | CYP2A6 (0.53) | CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL20102295 | 0.80 | TDP1 (0.43) | CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL20102298 | 0.80 | KDM4E (0.44) | CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL19386588 | 0.78 | CYP2C9 (0.50) | CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL20102296 | 0.76 | HCRTR1 (0.43) | CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800780-B2 | TDO2 Inhibitors | GENENTECH, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10233190-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2019-03-19 | — | — | US | disclosed |
| US-20190016726-A1 | TDO2 Inhibitors | PHARMARON BEIJING CO. LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
| US-20180118753-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2018-05-03 | — | — | US | disclosed |
| US-20180118753-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2018-05-03 | — | — | US | disclosed |
| WO-2017107979-A1 | TDO2 INHIBITORS | GENENTECH, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118753-A1 | IDO Inhibitors | IDO1, IDO2, INMT | CYP2E1 567/4885CYP2A6 894/4885CYP2C9 757/4885 |
| US-20190016726-A1 | TDO2 Inhibitors | TDO2, IDO2, IDO1 | CYP2E1 341/4885CYP2A6 456/4885CYP2C9 417/4885 |
| US-10233190-B2 | IDO inhibitors | IDO1, IDO2, INMT | CYP2E1 567/4885CYP2A6 894/4885CYP2C9 757/4885 |
| US-10800780-B2 | TDO2 Inhibitors | TDO2, IDO2, IDO1 | CYP2E1 341/4885CYP2A6 456/4885CYP2C9 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.